ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer.
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has ImmunoGen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IMU's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IMU underperformed the German Biotechs industry which returned 10% over the past year.
Return vs Market: IMU underperformed the German Market which returned 12.8% over the past year.
Price Volatility Vs. Market
How volatile is ImmunoGen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is ImmunoGen undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IMU (€4.98) is trading below our estimate of fair value (€8.54)
Significantly Below Fair Value: IMU is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IMU is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: IMU is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMU has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.
How is ImmunoGen forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMU's revenue (25.5% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: IMU's revenue (25.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMU's Return on Equity is forecast to be high in 3 years time
How has ImmunoGen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMU is currently unprofitable.
Growing Profit Margin: IMU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMU is unprofitable, and losses have increased over the past 5 years at a rate of -12.2% per year.
Accelerating Growth: Unable to compare IMU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: IMU's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is ImmunoGen's financial position?
Financial Position Analysis
Short Term Liabilities: IMU has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: IMU has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: IMU is debt free.
Reducing Debt: IMU's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: IMU has a low level of unsold assets or inventory.
Debt Coverage by Assets: IMU has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMU has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -9.3% each year.
What is ImmunoGen's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate IMU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IMU's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMU's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Enyedy (55yo)
Mr. Mark J. Enyedy has been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 and has been its interim principal financial officer since November 26, 2018. Mr. Enyedy has over ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD8.82M) is above average for companies of similar size in the German market ($USD1.20M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
|Executive VP||12.3yrs||US$2.12m||0.093% $805.6k|
|Senior Director of Corporate Communications & Investor Relations||0yrs||no data||no data|
|VP & Chief Human Resources Officer||1.6yrs||no data||no data|
|Senior Vice President of Regulatory Affairs & Quality||0yrs||no data||0.050% $431.5k|
|Senior VP & Chief Medical Officer||4.8yrs||US$998.87k||0.071% $617.0k|
Experienced Management: IMU's management team is considered experienced (4.3 years average tenure).
|Independent Chairman||10.3yrs||US$266.62k||no data|
|Independent Director||8.1yrs||US$230.62k||0.0057% $49.8k|
|Independent Director||8.1yrs||US$237.32k||no data|
|Independent Director||12.3yrs||US$233.62k||no data|
|Independent Director||2.1yrs||US$428.38k||no data|
|Independent Director||8.3yrs||US$226.89k||0.031% $267.9k|
Experienced Board: IMU's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.
ImmunoGen, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: ImmunoGen, Inc.
- Ticker: IMU
- Exchange: DB
- Founded: 1980
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$942.525m
- Listing Market Cap: US$867.689m
- Shares outstanding: 174.22m
- Website: https://www.immunogen.com
Number of Employees
- ImmunoGen, Inc.
- 830 Winter Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IMGN||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Nov 1989|
|IMU||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 1989|
|IMU||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Nov 1989|
|IMGN *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Nov 1989|
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/23 21:06|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.